IMPROVEMENT IN METABOLIC RISK FACTORS FOR CVD – (05-08-05)



Effect of orlistat on cardiovascular disease risk in obese adults

Just so you know–it wasn’t me that designated April/May as “beat up the pharmaceuticals for obesity” months.

This study found improvements in several metabolic risk factors for CVD, but not enough to lower 10-year risk assessment.  Interestingly, although the patients on orlistat had lower total cholesterol, none reduced their cholesterol lowering meds.  I can practically guarantee that lifestyle changes geared towards a healthy body composition will definitely lower a patient’s need for cholesterol lowering drugs.

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Categories: Heart Disease, Obesity and Weight Loss
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”